DexCom, Inc. $DXCM Stake Lessened by Vontobel Holding Ltd.

Vontobel Holding Ltd. trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 53.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,171 shares of the medical device company’s stock after selling 14,970 shares during the period. Vontobel Holding Ltd.’s holdings in DexCom were worth $1,137,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Reflection Asset Management purchased a new stake in DexCom in the fourth quarter valued at $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom during the first quarter worth about $25,000. Elevation Wealth Partners LLC grew its holdings in shares of DexCom by 61.0% during the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after purchasing an additional 152 shares during the last quarter. GK Wealth Management LLC purchased a new position in shares of DexCom during the third quarter worth about $35,000. Finally, Wellington Grp LLC increased its position in shares of DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In related news, EVP Michael Brown sold 1,700 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $85.48, for a total transaction of $145,316.00. Following the transaction, the executive vice president owned 98,185 shares of the company’s stock, valued at $8,392,853.80. This trade represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Foletta sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $85.32, for a total value of $170,640.00. Following the transaction, the director directly owned 48,852 shares in the company, valued at approximately $4,168,052.64. This represents a 3.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 24,257 shares of company stock valued at $2,049,173. Corporate insiders own 0.28% of the company’s stock.

DexCom Stock Down 0.1%

Shares of NASDAQ:DXCM opened at $85.98 on Tuesday. The stock has a market cap of $32.45 billion, a P/E ratio of 33.98, a P/E/G ratio of 1.44 and a beta of 1.48. The firm has a fifty day moving average price of $87.58 and a 200 day moving average price of $76.12. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same period last year, the firm posted $0.48 EPS. Sell-side analysts predict that DexCom, Inc. will post 2.64 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on DXCM. JPMorgan Chase & Co. boosted their target price on DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a report on Friday, July 31st. Weiss Ratings raised DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, October 6th. BTIG Research raised their price target on DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Royal Bank Of Canada restated an “outperform” rating and set a $105.00 price target (up from $90.00) on shares of DexCom in a research note on Thursday, October 1st. Finally, Stifel Nicolaus set a $95.00 price target on DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, DexCom has an average rating of “Buy” and an average price target of $92.43.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.